106 related articles for article (PubMed ID: 2080254)
1. [In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)].
Lellé RJ
Acta Histochem Suppl; 1990; 39():109-24. PubMed ID: 2080254
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
[TBL] [Abstract][Full Text] [Related]
3. [Determination of the growth fraction using monoclonal antibody Ki-67 in breast cancers].
Lellé RJ; Heidenreich W; Borsi C; Stauch G; Gerdes J
J Gynecol Obstet Biol Reprod (Paris); 1988; 17(4):485-9. PubMed ID: 3209828
[TBL] [Abstract][Full Text] [Related]
4. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells.
van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ
Cancer Res; 1989 Jun; 49(11):2999-3006. PubMed ID: 2720660
[TBL] [Abstract][Full Text] [Related]
5. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
[TBL] [Abstract][Full Text] [Related]
6. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
7. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining.
Raymond WA; Leong AS
J Pathol; 1989 Jul; 158(3):203-11. PubMed ID: 2769481
[TBL] [Abstract][Full Text] [Related]
8. [Ki 67 growth fraction in carcinomas and benign lesions of the breast].
Kunz J; Schmidt A
Zentralbl Pathol; 1993 Aug; 139(3):201-5. PubMed ID: 8218121
[TBL] [Abstract][Full Text] [Related]
9. Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas.
Gasparini G; Reitano M; Bevilacqua P; Meli S; Pozza F; Santini G
Anticancer Res; 1991; 11(4):1597-603. PubMed ID: 1746917
[TBL] [Abstract][Full Text] [Related]
10. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
Domagala W; Lasota J; Bartkowiak J; Weber K; Osborn M
Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
[TBL] [Abstract][Full Text] [Related]
11. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
13. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies.
Gerdes J
Semin Cancer Biol; 1990 Jun; 1(3):199-206. PubMed ID: 2103495
[TBL] [Abstract][Full Text] [Related]
15. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.
Marchetti E; Querzoli P; Marzola A; Bagni A; Ferretti S; Fabris G; Nenci I
Mod Pathol; 1990 Jan; 3(1):31-5. PubMed ID: 2308919
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
17. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors.
Patsouris E; Stocker U; Kallmeyer V; Keiditsch E; Mehraein P; Stavrou D
Anticancer Res; 1988; 8(4):537-44. PubMed ID: 3052245
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract][Full Text] [Related]
20. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
